panitumumab
amgen,takeda
['congrat', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
released the data of the #paradigm trial at #asco2022 confirming the value of #molecular_profiling and #sidedness as decision tools in #mcrc. congratulations to the authors and to for the brilliant discussion. i endorse the proposal 
Medical Oncology Department, Colon Cancer and Education Program at Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)